Tau PET Imaging in Atypical Dementias

University of Chicago70 enrolled

Overview

The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Primary Progressive Aphasia With Suspected Alzheimer's Disease

Interventions

18F-AV-1451DRUG

PETDEVICE

PET scanner for brain imaging

Eligibility

Sex: ALLMin age: 20 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have primary progressive aphasia Exclusion Criteria: * Pregnancy * Breastfeeding * Receiving radiation clinically

Locations (1)

University of Chicago - American School Building

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Tau levels in PPA participants

Tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) in cortical and medial temporal regions.

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.